vs

Side-by-side financial comparison of First Foundation Inc. (FFWM) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

First Foundation Inc. is the larger business by last-quarter revenue ($48.4M vs $27.6M, roughly 1.8× Zymeworks Inc.). Zymeworks Inc. runs the higher net margin — -71.0% vs -97.9%, a 26.9% gap on every dollar of revenue. On growth, First Foundation Inc. posted the faster year-over-year revenue change (421.7% vs 72.6%). Zymeworks Inc. produced more free cash flow last quarter ($-31.8M vs $-35.2M).

John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

FFWM vs ZYME — Head-to-Head

Bigger by revenue
FFWM
FFWM
1.8× larger
FFWM
$48.4M
$27.6M
ZYME
Growing faster (revenue YoY)
FFWM
FFWM
+349.1% gap
FFWM
421.7%
72.6%
ZYME
Higher net margin
ZYME
ZYME
26.9% more per $
ZYME
-71.0%
-97.9%
FFWM
More free cash flow
ZYME
ZYME
$3.4M more FCF
ZYME
$-31.8M
$-35.2M
FFWM

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FFWM
FFWM
ZYME
ZYME
Revenue
$48.4M
$27.6M
Net Profit
$-8.0M
$-19.6M
Gross Margin
Operating Margin
-97.5%
-80.1%
Net Margin
-97.9%
-71.0%
Revenue YoY
421.7%
72.6%
Net Profit YoY
43.0%
34.3%
EPS (diluted)
$-0.09
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FFWM
FFWM
ZYME
ZYME
Q4 25
$48.4M
Q3 25
$63.6M
$27.6M
Q2 25
$51.4M
$48.7M
Q1 25
$71.4M
$27.1M
Q4 24
$9.3M
$31.0M
Q3 24
$9.2M
$16.0M
Q2 24
$57.5M
$19.2M
Q1 24
$51.1M
$10.0M
Net Profit
FFWM
FFWM
ZYME
ZYME
Q4 25
$-8.0M
Q3 25
$-146.3M
$-19.6M
Q2 25
$-7.7M
$2.3M
Q1 25
$6.9M
$-22.6M
Q4 24
$-14.1M
$-23.5M
Q3 24
$-82.2M
$-29.9M
Q2 24
$3.1M
$-37.7M
Q1 24
$793.0K
$-31.7M
Operating Margin
FFWM
FFWM
ZYME
ZYME
Q4 25
-97.5%
Q3 25
-92.7%
-80.1%
Q2 25
-21.1%
-1.4%
Q1 25
8.8%
-94.5%
Q4 24
-247.7%
-71.6%
Q3 24
-1276.7%
-213.8%
Q2 24
4.6%
-222.9%
Q1 24
-0.2%
-376.9%
Net Margin
FFWM
FFWM
ZYME
ZYME
Q4 25
-97.9%
Q3 25
-230.1%
-71.0%
Q2 25
-15.0%
4.8%
Q1 25
9.7%
-83.5%
Q4 24
-152.2%
-75.8%
Q3 24
-896.9%
-186.6%
Q2 24
5.4%
-195.8%
Q1 24
1.6%
-315.6%
EPS (diluted)
FFWM
FFWM
ZYME
ZYME
Q4 25
$-0.09
Q3 25
$-1.78
$-0.26
Q2 25
$-0.09
$0.03
Q1 25
$0.08
$-0.30
Q4 24
$-0.24
$-0.32
Q3 24
$-1.23
$-0.39
Q2 24
$0.05
$-0.49
Q1 24
$0.01
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FFWM
FFWM
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$1.6B
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$912.6M
$320.1M
Total Assets
$11.9B
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FFWM
FFWM
ZYME
ZYME
Q4 25
$1.6B
Q3 25
$1.7B
$64.8M
Q2 25
$1.1B
$98.3M
Q1 25
$1.0B
$76.2M
Q4 24
$1.0B
$66.1M
Q3 24
$1.1B
$122.4M
Q2 24
$1.4B
$71.0M
Q1 24
$1.6B
$114.8M
Stockholders' Equity
FFWM
FFWM
ZYME
ZYME
Q4 25
$912.6M
Q3 25
$917.9M
$320.1M
Q2 25
$1.1B
$334.5M
Q1 25
$1.1B
$325.0M
Q4 24
$1.1B
$338.8M
Q3 24
$1.1B
$367.0M
Q2 24
$933.2M
$406.2M
Q1 24
$928.7M
$438.0M
Total Assets
FFWM
FFWM
ZYME
ZYME
Q4 25
$11.9B
Q3 25
$11.9B
$397.3M
Q2 25
$11.6B
$408.4M
Q1 25
$12.6B
$425.5M
Q4 24
$12.6B
$463.1M
Q3 24
$13.4B
$487.2M
Q2 24
$13.7B
$515.6M
Q1 24
$13.6B
$553.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FFWM
FFWM
ZYME
ZYME
Operating Cash FlowLast quarter
$-31.9M
$-31.4M
Free Cash FlowOCF − Capex
$-35.2M
$-31.8M
FCF MarginFCF / Revenue
-72.8%
-115.2%
Capex IntensityCapex / Revenue
6.9%
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-45.9M
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FFWM
FFWM
ZYME
ZYME
Q4 25
$-31.9M
Q3 25
$9.2M
$-31.4M
Q2 25
$-16.3M
$12.1M
Q1 25
$-552.0K
$-3.4M
Q4 24
$-8.7M
$-41.5M
Q3 24
$14.2M
$-5.9M
Q2 24
$-9.1M
$-25.0M
Q1 24
$7.2M
$-37.7M
Free Cash Flow
FFWM
FFWM
ZYME
ZYME
Q4 25
$-35.2M
Q3 25
$8.6M
$-31.8M
Q2 25
$-16.7M
$11.6M
Q1 25
$-2.5M
$-3.4M
Q4 24
$-11.4M
$-41.8M
Q3 24
$13.4M
$-6.8M
Q2 24
$-9.4M
$-25.6M
Q1 24
$5.9M
$-37.9M
FCF Margin
FFWM
FFWM
ZYME
ZYME
Q4 25
-72.8%
Q3 25
13.5%
-115.2%
Q2 25
-32.4%
23.7%
Q1 25
-3.5%
-12.6%
Q4 24
-123.5%
-134.8%
Q3 24
146.2%
-42.4%
Q2 24
-16.3%
-133.0%
Q1 24
11.6%
-377.5%
Capex Intensity
FFWM
FFWM
ZYME
ZYME
Q4 25
6.9%
Q3 25
1.0%
1.5%
Q2 25
0.8%
1.1%
Q1 25
2.8%
0.1%
Q4 24
29.4%
1.0%
Q3 24
9.0%
5.6%
Q2 24
0.4%
3.1%
Q1 24
2.5%
1.8%
Cash Conversion
FFWM
FFWM
ZYME
ZYME
Q4 25
Q3 25
Q2 25
5.21×
Q1 25
-0.08×
Q4 24
Q3 24
Q2 24
-2.96×
Q1 24
9.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons